All In Biotech

Drug Trial Radar · NCT07154290

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Mar 18, 2026

Primary completion

Jun 10, 2030

Study completion Jun 10, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and marlotamig work(s) * The side effects that ubamatamab and marlotamig might cause * How much ubamatamab and marlotamig is in the blood at different times * If the body makes antibodies to ubamatamab and/or marlotamig, this may cause the ubamatamab to not work as well

Conditions

  • Non Small Cell Lung Cancer
  • Advanced Non Small Cell Lung Cancer
  • Metastatic Non Small Cell Lung Cancer
  • Carcinoma Non Small Cell Lung

Interventions

  • UbamatamabDrug

    Administered per the protocol

  • MarlotamigDrug

    Administered per the protocol

  • SarilumabDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 5 years

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Cancer Treatment Centers of America, Phoenix

    Goodyear, Arizona · Recruiting

  • The City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • ChristianaCare Health System

    Newark, Delaware · Recruiting

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

  • University of Illinois Chicago

    Chicago, Illinois · Recruiting

  • Franciscan Health

    Munster, Indiana · Recruiting

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • University of Texas Medical Branch

    Galveston, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Baylor Scott & White Health

    Temple, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.